Has Russell Zwiener received payments from drug or device companies?

Yes. Drug and device makers reported $2,611 in general payments to Russell Zwiener across 88 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Russell Zwiener did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Russell Zwiener come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Russell Zwiener

Pediatric Gastroenterology · New Orleans, LANPI 1194012187

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 88 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 21.1% — the pattern of someone who eats at a lot of different presentations.

$2,611in general payments, 2019–2025

Across 88 payments — averaging $29.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$552
Alcresta Therapeutics, Inc.$316
Conmed Corporation$312
Boston Scientific$258
Olympus America Inc.$216
Travere Therapeutics, Inc.$215
plus $743 from 16 others

What the payments were for

Food & beverage$2,611100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	28	$552
Alcresta Therapeutics, Inc.	11	$316
Conmed Corporation	3	$312
Boston Scientific	4	$258
Olympus America Inc.	3	$216
Travere Therapeutics, Inc.	9	$215
Mirum Pharmaceuticals, Inc.	9	$191
Neuraxis, Inc.	1	$133
Takeda Pharmaceuticals U.S.A., Inc.	2	$55
Amgen	2	$51
Shire North American Group Inc	2	$41
QOL Medical, LLC	2	$41
Sanofi	2	$35
Albireo Pharma, Inc.	2	$34
Ipsen Biopharmaceuticals, Inc	1	$27
Orphalan Inc	1	$23
Medtronic	1	$22
Steris Corporation	1	$20
AstraZeneca	1	$19
Boehringer Ingelheim	1	$18
Ironwood Pharmaceuticals, Inc	1	$17
Pfizer	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,611 in reported general payments places this provider in the 85th percentile of 30 pediatric gastroenterology providers in Louisiana.

See all pediatric gastroenterology providers in Louisiana →

Other pediatric gastroenterology in New Orleans

Ryan HimesNew Orleans$114K
Patricio AriasNew Orleans$90K
Brian MorrisNew Orleans$3K
Amanda GlinkyNew Orleans$2K
Colleen LeblancNew Orleans$2K
Darnna BanksNew Orleans$2K
Matthew GieferNew Orleans$2K
Michael CarverNew Orleans$1K
Jasmeet MokhaNew Orleans$691
Erika SmithNew Orleans$667

See the full list for Louisiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →